Dr. Abdelrahman Elsingergy

(Regional Product Manager)

PORT GHALEB 4th Feb 2015

SPIMACO ADDWAEIH

Saudi Pharmaceutical Industries & Medical Appliances Co.

Introduction

Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) is a Saudi Joint–Stock company ,established in 1986.

SPIMACO is the only Saudi Pharmaceutical

Company listed and quoted in the Saudi Stock Market.

In order to meet its future expansion plans,

SPIMACO has increased its capital by 30%, to produce more products that serve its

community .

SPIMACO ADDWAEIH is committed to provide high quality pharmaceutical products meeting international standards that earn the loyalty of its regional and international customers through Internal Development and Strategic Alliances to benefit its society.

Mission

Therapeutic Classes

• SPIMACO manufactures & markets more than 250 Products in various markets to cover wide range of therapeutic areas:

NSAIDs Analgesics Antibiotics Erectile Dysfunction Anti-Diabetics

Antihypertensives Anti- Hyperlipidemics Anti-Allergics Heamatinics Anti-Ulceratives Other GIT products

SPIMACO ADDWAEIH

Major Strengths

State of Art Al-Qassim Pharmaceutical Plant is located Northwest of Riyadh.

150,000m2 is dedicated to Production and the rest for Warehousing, Labs, Product Development and Administrative activities.

Manufacturing Capabilities

Manufacturing Capabilities

• SPIMACO is known to exceed international standards and high levels of manufacturing and quality employing state-of-the art manufacturing facilities.

• SPIMACO is implementing SAP system which makes it the only pharmaceutical company to employ such advanced system regionally.

• SPIMACO is ISO (ISO 9001 - 2000 and ISO 14000 Environmental Management System) certified Company.

King Fahad & King Abdul Aziz Quality Awards

Environment Compliance Certificate.

Manufacturing Capabilities

FDA used Spimaco facility as a training model for Saudi MOH officials & has ranked SPIMACO as among the top ten in the region due to the high standard of its design and the powerful GMP quality system implemented in the plant.

Manufacturing Capabilities

Certified

• Strategic decision was made very early to establish a nucleus for a research center focusing on the sophisticated field of Biotechnology.

• The unit is an extension to a joint research program with King Abdulaziz City for Science and Technology (KACST).

• This unit was furnished under the guidance of Good

Laboratory Practice (GLP). Qualified research scientists and technical staff were carefully selected.

• All the required production and laboratory equipments were sourced from the well-known European, US and Canadian manufactures for biotech equipment.

• Expertise of a European corporation specialized in this field was obtained.

Biotech Unit

SPIMACO ADDWAEIH Existing Major Business Alliances

SPIMACO Major Alliances

FULL MARKETING LICENSES

CO-MARKETING LICENSE

SPIMACO Major Alliances

MANUFACTURING UNDER-LICENSE

BRAND ACQUISITION

Snafi (2nd brand of CIALIS)

o Klavox (2nd brand of AUGMENTIN)

•Lorine (2nd brand of CLARITINE) •Neorin (2nd brand of AERIUS) •Lorinase Syrup

o Hymox (2nd brand of AMOXIL)

Out Licensing

•Sitagliptin (2nd brand of Januvia) •Etirocoxib (2nd brand of Arcoxia) •Montelukast (2nd brand of Singulair)

Fevadol Range

Verine

Otricold

Clarinase Syp

Recormon

Ceclor & Keflex

DISTRIBUTION ALLIANCE

Biotech Unit

Spimaco Footprint in MENA Region

Spimaco Footprint in MENA Region

65 Sales and

Marketing staff

90 Sales and

Marketing staff

15 Sales and

Marketing staff

16 Sales and

Marketing staff

• 6 Sales and

Marketing staff

• 33 Sales and

Marketing staff

• 6 Sales and

Marketing staff

234 Sales and

Marketing staff

• 5 Sales and

Marketing staff

• 16 Sales and

Marketing staff

12 Sales and

Marketing staff

More than 500 Sales &

Marketing Staff,

SPIMACO Has one of

The largest Sales

forces In the MENA

region

SPIMACO ADDWAEIH Updated Sales Report

Updated Sales Report YTD 2’2013

SPIMACO ranks the 1st position in Saudi Pharma (Private) market, as

per own products with 56.9% growth

Also, SPIMACO ranks the 1st position in Saudi Pharma ( Private) Market,

as per sales include Licensors’ products with 53.3% growth

SPIMACO grew by 50.1Mio SR

Source : IMS –SAPI- 2’13

Top 10 Manufacturers, YTD 2’2013

Saudi Pharma Market (Private)

0

20

40

60

80

100

120

140

Va

lue

Mio

SR

+56.9%

+12.6%

-3.1%

+31.4% -8.2%

+8.5%

+25.8%

+18%

+11.9%

+43.9%

Spimaco Own Products Only

Growth%

MS% 7.8% 6.3% 3.7% 4.7% 4.6% 4.1% 3.2% 2.7% 2.4% 2.2%

Value mil SR 138.3 112.1 101.8 83 82 72.4 56.7 47.3 43 38.4

Top 10 Manufacturers, Spimaco occupies the first rank with 53.3% Growth and 9% MS

0

20

40

60

80

100

120

140

160

Spimaco Tabuk GSK Julphar Pfizer Jamjoom Novartis Astra MSD Aventis

Va

lue

Mio

SR

+53.3%

+12.6%

-3.1%

+31.4% -8.2%

+8.5%

+25.8

% +18%

+11.9

% +43.9

%

Growth%

MS% 9% 6.3% 5.7% 4.7% 4.6% 4.1% 3.2% 2.7% 2.4% 2.2%

Value mil SR 159.8 112.1 101.8 83 82 72.4 56.7 47.3 43 38.4

Spimaco Products including Licensors

Top 10 Leading Products By Value

0

5

10

15

20

25

30

35

40

45

50

Growth%

Mio

SR

MS% 2.7% 1.1% 0.9% 0.8% 0.7% 0.7% 0.7% 0.7% 0.6% 0.6%

Value mil SR 46.9 18.8 15 13.9 13.1 12.9 11.8 11.5 11.4 11.1

+308.3%

+22.1%

SPIMACO has 2 products out of 10

SPIMACO 2011 NEWS

Spimaco acquired a 48% stake in Eirgen

Pharma

Spimaco acquired a 48% stake in

Eirgen Pharma

A LISTED Saudi Arabian company has acquired a 48 per cent stake in Waterford-based pharmaceutical firm EirGen for €19 million.

Saudi Pharmaceutical Industries and Medical Appliances Corp (Spimaco) is one of the largest pharmaceutical companies in the Middle East. The Riyadh-based company, which had previously indicated its intention to expand into Europe, is listed on the Saudi stock exchange.

EirGen’s products are already licensed throughout Europe, the United States, Canada and, most recently, Japan, a key advantage for the company, which hopes to increase its presence in global markets.

The company sells its products across 45 countries and has partnerships with pharmaceutical companies across the world, including in South African, Uruguay, and across Europe.

SPIMACO ADDWAEIH is committed to provide high quality pharmaceutical products meeting international standards that earn the loyalty of its regional and international customers through internal development and strategic alliances to benefit its society.

Mission

THANK YOU

Abdelrahman Elsingergy

Regional Product Manager

SPIMACO ADDWAEH

PORT GHALEB 4th Feb 2015

• Over 16 years history for 340 Mio. Patients worldwide

• Gold standard for many types of infections especially UTIs

• 100,000 Patients enrolled for trials all over the world

• Minimal bacterial resistance in spite of geographical magnitude of the

problem

-International Journal of Urology .July.2004

Ciprofloxacin – SCOOP

1. Binding to bacterial enzyme DNA gyrase , and

consequently inhibiting DNA replication and transcription

2. Destroys the bacterial cell envelope, resulting in quick

bacterial death

Mode of Action

Cystitis

Cystitis

Cystitis

Pyelonephritis

Prostatitis

250 mg 17 L.E.

500 mg 33 L.E.

750 mg 40 L.E.

Algeria Libya

Egypt

Lebanon

KSA

Kuwait

Bahrain Qatar

UAE

Oman

A Growing International Brand in 10 countries

THANK YOU